The invention relates to compounds of formula (I), wherein R1 is phenyl or pyridinyl, optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen and lower alkoxy substituted by halogen； X1 is -N= or CH； X2 is CR2 or =N-； X3 is -N= or CH； with the proviso that only two of X1, X2 or X3 are nitrogen； wherein is a triazole group, selected from R2 is hydrogen or lower alkyl； Z is a bond, -O- or -CH2-； or to pharmaceutically suitable acid addition salts thereof. It has now been found that the compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.La invención se refiere a compuestos de la fórmula (I), en donde R1 es fenilo o piridinilo, opcionalmente sustituido por halógeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno y alcoxi inferior sustituido por halógeno； X1 es -N = o CH； X2 es CR2 o = N-； X3 es -N o CH； con la condición de que sólo dos de X1, X2 o X3 son nitrógeno； en donde es un grupo triazol, seleccionado de R2 es hidrógeno o alquilo inferior； Z es un enlace, -O- o -CH2-； o a sales de adición de ácido farmacéuticamente apropiadas de los mismos. Ahora se ha encontrado que los compuestos de la fórmula I tienen una buena afinidad a los receptores asociados con aminas traza (TAARs), especialmen
